Revisiting pulmonary vein isolation alone for persistent atrial fibrillation: A systematic review and meta-analysis

• Published in: Heart rhythm Vol. 14; no. 5; pp. 661 - 667
• Main Authors: Voskoboinik, Aleksandr, MBBS, Moskovitch, Jeremy T., BSc, MD, Harel, Nadav, BSc, MD, Sanders, Prashanthan, MBBS, PhD, FHRS, Kistler, Peter M., MBBS, PhD, FHRS, Kalman, Jonathan M., MBBS, PhD, FHRS
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.05.2017
• Subjects: Ablation; Arrhythmia; Atrial fibrillation; Atrial Fibrillation - surgery; Cardiovascular; Catheter Ablation - methods; Cryoballoon; Humans; Pulmonary vein isolation; Pulmonary Veins - surgery; Arrhythmia; Ablation; Cryoballoon; Atrial fibrillation; Pulmonary vein isolation
• ISSN: 1547-5271; 1556-3871
• DOI: 10.1016/j.hrthm.2017.01.003

Background Early studies demonstrated relatively low success rates for pulmonary vein isolation (PVI) alone in patients with persistent atrial fibrillation (PeAF). However, the advent of new technologies and the observation that additional substrate ablation does not improve outcomes have created a new focus on PVI alone for treatment of PeAF. Objective The purpose of this study was to systematically review the recent medical literature to determine current medium-term outcomes when a PVI-only approach is used for PeAF. Methods An electronic database search (MEDLINE, Embase, Web of Science, PubMed, Cochrane) was performed in August 2016. Only studies of PeAF patients undergoing a ”PVI only” ablation strategy using contemporary radiofrequency (RF) technology or second-generation cryoballoon (CB2) were included. A random-effects model was used to assess the primary outcome of pooled single-procedure 12-month arrhythmia-free survival. Predictors of recurrence were also examined and a meta-analysis performed if ≥4 studies examined the parameter. Results Fourteen studies of 956 patients, of whom 45.2% underwent PVI only with RF and 54.8% with CB2, were included. Pooled single-procedure 12-month arrhythmia-free survival was 66.7% (95% confidence interval [CI] 60.8%–72.2%), with the majority of patients (80.5%) off antiarrhythmic drugs. Complication rates were very low, with cardiac tamponade occurring in 5 patients (0.6%) and persistent phrenic nerve palsy in 5 CB2 patients (0.9% of CB2). Blanking period recurrence (hazard ratio 4.68, 95% CI 1.70–12.9) was the only significant predictor of recurrence. Conclusion A PVI-only strategy in PeAF patients with a low prevalence of structural heart disease using contemporary technology yields excellent outcomes comparable to those for paroxysmal AF ablation.